{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:13:47Z","timestamp":1793978027460,"version":"4.8.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Thyroid eye disease (TED) primarily occurs in hyperthyroid patients, sometimes resulting in poor visual prognosis. Although other autoimmune diseases have been reported to be associated with serum programmed cell death 1 (PD-1), the relationship with TED remains unknown. This study investigated the relationship between TED and immune checkpoint molecules.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum immune checkpoint molecules were measured in TED and control patient blood samples. In TED patients, blood samples were compared before and 6 months after steroid pulse treatment. Cytometry analysis was additionally performed in TED and control patients to compare the expression of (PD-1) of T cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Serum concentrations of PD-1 in TED and control patients were 163.49 \u00b1 79.01 (pg\/mL) and 123.58 \u00b1 46.61 (pg\/mL) (<jats:italic>P<\/jats:italic> = 0.03). Serum PD-L1 concentration in TED was 157.89 \u00b1 55.34 (pg\/mL), while 152.58 \u00b1 22.70 (pg\/mL) in control patients (<jats:italic>P<\/jats:italic> = 0.92). For flow cytometry analysis, the mean fluorescence intensity (MFI) ratio of PD-1 in Foxp3high CD45RA- of the CD4+ T cells and CD127-CD25high of the CD4+ T cells were higher in TED versus control patients (<jats:italic>P<\/jats:italic> = 0.04, <jats:italic>P<\/jats:italic> = 0.02). There was also a higher percentage of PD-1 expressions on CD4+ T cells and Foxp3high CD45- T cells in TED patients versus that for control patients (<jats:italic>P<\/jats:italic> &amp;lt; 0.001, <jats:italic>P<\/jats:italic> = 0.003).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PD-1 expression of CD4+Foxp3+ regulatory T cells appear to be associated with TED pathogenesis before and after treatment. Regulatory T cells expressed PD-1 have possibilities of clinical activity and autoimmune pathology of TED.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fopht.2024.1491053","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:20:00Z","timestamp":1734330000000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Serum PD-1 regulation and PD-1 expression of CD4+Foxp3+ regulatory T cells in patients in thyroid eye disease associated with immunosuppression treatment"],"prefix":"10.3389","volume":"4","author":[{"given":"Atsushi","family":"Sakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Tagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Misawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Haruna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4274\/tjo.80688","article-title":"Thyroid-associated ophthalmopathy","volume":"47","author":"\u015eahl\u0131","year":"2017","journal-title":"Turk J Ophthalmol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702603","article-title":"Cigarette smoking and thyroid eye disease: a systematic review","volume":"21","author":"Thornton","year":"2007","journal-title":"Eye (Lond)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves\u2019 disease: A meta-analysis and systematic review","volume":"93","author":"Chin","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01792.x","article-title":"Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease","volume":"127","author":"Ludgate","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease: review and update on molecular mechanisms","volume":"100","author":"Khong","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000132","article-title":"The pathophysiology of thyroid eye disease","volume":"34","author":"Shan","year":"2014","journal-title":"J Neuro-Ophthalmol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2169\/naika.99.755","article-title":"Therapy-resistant thyroid diseases. 1.Graves\u2019 ophthalmopathy","volume":"99","author":"Hiromatsu","year":"2010","journal-title":"Nihon Naika Gakkai Zasshi"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci Adv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","article-title":"PD-1\/PD-L1and autoimmunity: a growing relationship","volume":"310","author":"Zamania","year":"2016","journal-title":"Cell Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000485742","article-title":"Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment","volume":"7","author":"Campredon","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/197140091302600509","article-title":"Disease activity in Graves\u2019 ophthalmopathy: diagnosis with orbital MR imaging and correlation with clinical score","volume":"26","author":"Tortora","year":"2013","journal-title":"Neuroradiol J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/678194","article-title":"Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy: A prospective study","volume":"2015","author":"Kampmann","year":"2015","journal-title":"Int J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-018-0336-8","article-title":"Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis","volume":"6","author":"Elias","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-012-9496-8","article-title":"CD4(+)CD25 (+)CD127 (low\/-) T cells: a more specific Treg population in human peripheral blood","volume":"35","author":"Yu","year":"2012","journal-title":"Inflammation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13643-020-01459-7","article-title":"Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature","volume":"9","author":"Mu\u00f1oz-Ortiz","year":"2020","journal-title":"Syst Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05919.x","article-title":"The role of the PD-1 pathway in autoimmunity and  peripheral tolerance","volume":"1217","author":"Fife","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00948.x","article-title":"Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases","volume":"102","author":"Mataki","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"B22","article-title":"Enhanced expression of programmed death-1 (PD-1)\/PD-L1 in salivary glands of patients with Sj\u00f6gren\u2019s syndrome","volume":"32","author":"Kobayashi","year":"2005","journal-title":"J Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.10.5015","article-title":"Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease","volume":"164","author":"Oaks","year":"2000","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-021-01498-3","article-title":"Insulin\/IGF-1 signaling promotes immunosuppression via the STAT3 pathway: impact on the aging process and age-related diseases","volume":"70","author":"Salminen","year":"2021","journal-title":"Inflamm Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.12.2205","article-title":"Viral immune evasion due to persistence of activated T cells without effector function","volume":"188","author":"Zajac","year":"1998","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01177-06","article-title":"PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion","volume":"80","author":"Urbani","year":"2006","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.2.7338","article-title":"Pathogenesis of Graves\u2019 ophthalmopathy\u2013current understanding","volume":"86","author":"Wiersinga","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00613.x","article-title":"Analysis of orbital T cells in thyroid-associated ophthalmopathy","volume":"112","author":"F\u00f6rster","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2007.04.012","article-title":"PD-1 and its ligands in T-cell immunity","volume":"19","author":"Keir","year":"2007","journal-title":"Curr Opin Immunol"}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2024.1491053\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:20:02Z","timestamp":1734330002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2024.1491053\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":31,"alternative-id":["10.3389\/fopht.2024.1491053"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2024.1491053","relation":{},"ISSN":["2674-0826"],"issn-type":[{"value":"2674-0826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"article-number":"1491053"}}